Corporate Social Responsibility Orgninal

8/6/2019 Corporate Social Responsibility Orgninal

1/22

- Corporate social responsibility.

-Garima Rajpurohit

TY-BMS B78.


2/22

Introduction..

What is corporate socialresponsibility????Different organizations have framed different definitions - although

there is considerable common ground between them. My own definition isthat CSR is about how companies manage the business processes to produce anoverall positive impact on society.

"Corporate Social Responsibility is the continuing commitment by business tobehave ethically and contribute to economic development while improving thequality of life of the workforce and their families as well as of the local communityand society at large Corporate Social Responsibility (CSR) has been on theagenda in India for a considerable period. Most big Indian corporations areengaged in some CSR activities. As is the case in many countries, the privatesector is generally more active in this area than the governmental/public sector.Several major CSR initiatives havebeen launched in India since themid-1990s. Among these is the firstvoluntary code of corporategovernance, Desirable Corporate

Governance: A Code, established inApril 1998. This was an initiative bythe Confederation of Indian Industry(CII),Indias largest industry andbusiness association. The rationale for CSR has beenarticulated in a number of ways. Inessence it is about buildingsustainable businesses, which needhealthy economies, markets andcommunities.

The key drivers for CSR are:

Enlightened self-interest - creating a synergy of ethics, a cohesive societyand a sustainable global economy where markets, labor and communitiesare able to function well together.

Social investment - contributing to physical infrastructure and social capitalis increasingly seen as a necessary part of doing business.


3/22

Transparency and trust - business has low ratings of trust in publicperception. There is increasing expectation that companies will be moreopen, more accountable and be prepared to report publicly on theirperformance in social and environmental arenas .

Intoduction to Glaxosmithkline

Established in the year 1924 in India GlaxoSmithKline PharmaceuticalsLtd. is one of the oldest pharmaceuticals company and employs over 3500people. Globally,. In India, they are one of the market leaders with a turnover ofRs. 2080 crore and a share of 5.1%*. At GSK, the mission is to improve thequality of life by enabling people to do more, feel better and live longer. Thismission drives Gsk to make a real difference to the lives of millions of people withtheir commitment to effective healthcare solutions.

GlaxoSmithKline one of the world's leading research-based pharmaceutical and

healthcare companies is committed to improving the quality of human life byenabling people to do more,feel better and live longer.theGSK India product portfolioincludes prescriptionmedicines and vaccines. Theprescription medicines rangeacross therapeutic areas suchas anti-infectives, dermatology,gynaecology, diabetes,oncology, cardiovascular

disease and respiratorydiseases. GSK also offers arange of vaccines, for theprevention of hepatitis A,hepatitis B, invasive diseasecaused by H, influenzae,chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer andothers.GSK has two manufacturing units in India, located at Nashik and Thane aswell as a clinical development centre in Bangalore. The state of art plant atNashik makes formulations while bulk drugs and the active pharmaceuticalingredients are manufactured at Thane.

Being a leader brings responsibility towards the communities in which weoperate. At GSK, we have a Corporate Social Responsibility program that workstowards fulfilling basic healthcare, education and other developmental needs ofthe underserved population. With this dedication and commitment, we believethat the world will be better, healthier and happier.


4/22

GSK is committed to developing new and effective healthcare solutions. Thevalues on which the group was founded have always inspired growth and willcontinue to do so in times to come.

GSK worldwide One of the world's leading research-based pharmaceutical and healthcarecompanies.

employ over 96,500 people in over 100 countries

Around 13,000 people work in our research teams across the world to discovernew medicines

vaccines are included in immunisation campaigns in 182 countries worldwide

Every second, they distribute more than 35 doses of Vaccines.

Every minute, more than 1100 prescriptions are written for GSK products.

January 2008 marked the tenth anniversary of their programme to help eliminatelymphatic filariasis (elephantiasis). Since the start of this programme they havedonated more than 1.4 billion albendazole tablets to countries affected by LF.

global community investmentand charitable donations were 222million in 2010

GSK India In India, GSK is one of the marketleaders with a turnover of Rs. 2080crore and a share of 5.1 percent

GSK leads in several therapeuticsegments - dermatology, anti-helmentics, hormones[source: IIPA,Dec MAT 2010]

GSK has 7 products in the top 50 brands, and the top five GSK products areAugmentin, Calpol, Ceftum, Phexin, and Betnesol[source: IIPA, Dec MAT 2010]

GSK's vaccines division is ranked first in a fast-growing vaccines market. Someleading products in India are Havrix, Varilrix, Rotarix, Hiberix and Cervarix[source: Vaccines audit Dec MAT 2010]

GSK India's R&D centres at Thane and Nashik have been granted recognition bythe Department of Scientific and Industrial Research, Government of India


5/22

The number of clinical studies conducted in India is rapidly growing across a rangeof therapy areas

GSK India's social responsibility programmes focus on development of underdeveloped villages, women, children and aged, specifically in the areas of healthcareand education

Management at GlaxoSmithKlineGlaxoSmithKline India is managed by the Board of Directors and the India Management

Team.

Board of directors

D.S. Parekh - Chairman & Non - Executive Director

V. Thyagarajan - Vice-Chairman & Non - Executive Director

Dr. H. B. Joshipura - Managing Director

R. R. Bajaaj- Independent Director

GSK India Management Team

Dr. H. B. Joshipura - Chairman

M.B. Kapadia - Senior Executive Director


6/22

Dr. A. Banerjee - Sr. Executive Director - Technical

Products of GlaxoSmithKline..

The GSK India product portfolio includes prescription

medicines and vaccines. prescription medicines range

across therapeutic areas such as anti-infectives,

dermatology, gynaecology, diabetes, cardiovascular

disease and respiratory diseases. The company is the

market leader in most of the therapeutic categories inwhich it operates. GSK also offers a range of vaccines,

for the prevention of hepatitis A, hepatitis B, invasive

disease caused by H, influenzae, chickenpox, diphtheria,

pertussis, tetanus and others.

Prescription medicines Analgesic.

Anti-Infective.

Anti-Inflammatory.

Anti-Parasitic.

Cardiovascular.

Dermatology.

Diabetes..

Endocrine.

Gastrointestinal.

Gynaecology.

Immunosupressants.

Nutritional. Respiratory.

CNS.

Oncology.

Vaccines Boostrix.
http://www.gsk-india.com/product-prescriptionmedicines.htmlhttp://www.gsk-india.com/product-prescriptionmedicines.htmlhttp://www.gsk-india.com/product-antiinfective.htmlhttp://www.gsk-india.com/product-antiinflammatory.htmlhttp://www.gsk-india.com/product-antiparasitic.htmlhttp://www.gsk-india.com/product-cardiovascular.htmlhttp://www.gsk-india.com/product-dermatology.htmlhttp://www.gsk-india.com/product-diabetes.htmlhttp://www.gsk-india.com/product-endocrine.htmlhttp://www.gsk-india.com/product-gastrointestinal.htmlhttp://www.gsk-india.com/product-gastrointestinal.htmlhttp://www.gsk-india.com/product-gynaecology.htmlhttp://www.gsk-india.com/product-immuno.htmlhttp://www.gsk-india.com/product-nutritional.htmlhttp://www.gsk-india.com/product-nutritional.htmlhttp://www.gsk-india.com/product-respiratory.htmlhttp://www.gsk-india.com/product-cns.htmlhttp://www.gsk-india.com/product-Oncology.htmlhttp://www.gsk-india.com/product-vaccines.htmlhttp://www.gsk-india.com/product-prescriptionmedicines.htmlhttp://www.gsk-india.com/product-antiinfective.htmlhttp://www.gsk-india.com/product-antiinflammatory.htmlhttp://www.gsk-india.com/product-antiparasitic.htmlhttp://www.gsk-india.com/product-cardiovascular.htmlhttp://www.gsk-india.com/product-dermatology.htmlhttp://www.gsk-india.com/product-diabetes.htmlhttp://www.gsk-india.com/product-endocrine.htmlhttp://www.gsk-india.com/product-gastrointestinal.htmlhttp://www.gsk-india.com/product-gynaecology.htmlhttp://www.gsk-india.com/product-immuno.htmlhttp://www.gsk-india.com/product-nutritional.htmlhttp://www.gsk-india.com/product-respiratory.htmlhttp://www.gsk-india.com/product-cns.htmlhttp://www.gsk-india.com/product-Oncology.htmlhttp://www.gsk-india.com/product-vaccines.htmlhttp://www.gsk-india.com/product-prescriptionmedicines.html


7/22

Cervarix .

Engerix-B.

Fluarix.

Havrix.

Hiberix.

Infanrix.

Mencevax ACWY.

Priorix.

Rotarix.

Tritanrix-HB.

Corporate Social Responsibility atGsk.

It is a research-based pharmaceutical company whose mission is to improve thequality of human life by enabling people to do more, feel better and live longer.Theybelieve in making a valuable contribution to society by developing and marketingmedicines which improve people's lives through their business. The philosophy is totarget support to selected programs that are innovative, sustainable and which producetangible results.

CSR in IndiaGlaxoSmithKline is linked closely to the communities which operate- locally, nationallyor globally. They do not exist in isolation. All their actions are focused around this feelingof being centered.

mission statement og Gsk "To lend a helping hand to the underserved in our society

through the support of women, children and the aged in the areas of health andeducation." Implementing this philosophy in spirit, we make a positive contribution to thecommunities in which we operate, and invest inhealth and education programs andpartnerships that aim to bring sustainableimprovements to underserved people.

core value - we careBeing a premier pharmaceutical company in thecountry, GSK's core value is to be a goodcorporate citizen. It is committed to the

communities in which it works. Support to thecommunity through charitable initiatives is theway through which it invests in society. This isdone byBeing proactive in improving theenvironment, Participating and contributingactively for Tribal Welfare.Their initiatives areprimarily focused towards women, children andthe aged and are directed in the areas of Health


8/22

and Education. They believe that these areas are related and of direct concern to GSK. Ifthere is proper education, one will eventually learn to be hygienic, and if one is hygienic,will one remain healthy. The organization facilitates in educating masses on goodpractices of healthy living.

At GlaxoSmithKline India, the activities towards community development are attached tothe Corporate Communications Department. Since 1970, the Company has been

implementing various social responsibility activities apart from statutory ones. Thefollowing Community Development activities are carried out through the company'sCorporate Social Responsibility Department situated at its Head Office in Mumbai.

What they do.They provide money, medicines, time and equipment to non-profit organizations to helpimprove health and education in underserved communities. focusing on programs thatare 'innovative, sustainable and bring real benefits to those most in need'.

Ethical Conduct.

GSK is building on a strong ethical culture by developing robust policies,

recruiting the right people and equipping them with the information they needto make ethical decisions. Putting patients first is the core principle of being an

ethical healthcare company.

The Code of Conduct sets out fundamental standards for

all employees. It is supported by the Employee Guide to

Business Conduct which helps employees make ethical

decisions and emphasizes GSKs key values:


9/22

Commit to transparency

Show respect for people

Always demonstrate the highest integrity in our conduct.

Be patient focused

In 2009, Bureau Veritas assured the Ethical Conduct section of their CR

Report and made recommendations for how we could improve our

approach and reporting. They have taken these recommendations into

account in the improvements they made to the policies and processes

during 2010.

Work with communitiesGsK believe that business has an important role to play in society and the contributionmade through community investment is a key element of this.The aim is to useresources to deliver value to both communities and to their business.The supportincludes donations of time, money, expertise and medicines. Most of the investment ismade through specialist non-profit organisations, which are best placed to understandlocal community needs and target resources effectively. They partner with and supportorganisations whose goals andobjectives reflect our mission toimprove the quality of humanlife.

programmes include strategicglobal initiatives, designed totackle diseases of thedeveloping world acrossmultiple countries.alsosupporting local programmesthat are tailored to the specificneeds and challenges of manydifferent markets. These arefocused on the issues of healtheducation, access to medicines

and scienceeducation.

The aim to maximise the benefits of our community investment by selecting projectsthat are relevant to business and enable them to use expertise and resources. As wellas benefiting communities, investment strengthens business by improving theirreputation, boosting employee morale and helping us build relationships based onmutual understanding with a range of stakeholders.


10/22

Improving access to healthcare is one of the main priorities for community investment.They also invest inprogrammes that create opportunities in education and economic development. Supportfor science education is particularly important because of the growing shortage ofscience graduates in some of themarkets. Investing in education will help them toensure the long-term sustainability of business and commitment to improve access tomedicines and healthcare. They support a small number of arts and environmentalinitiatives, particularly those with a health focus. encourageing employees to getinvolved because this benefits the organisations and charities Gsk support, contributestoemployees personal development and supports our reputation. Every employee at GSKis entitled to one paid day off each year to volunteer in the community. They also runPULSE which enables high-performing employees to share their expertise and learn fromNGO partners through 36 month placements.GsK support to bring long-term sustainablebenefits.they also help community organisations to plan for the time when their supportfinishes and help them win funding from other sources.

Global programmes.

ApproachIn developing countries millions of people continue to suffer and die from preventable or

treatable diseases. Gsk global health programmes are designed to improve the health

and quality of life for people in these communities through provision of medicines,

education and advocacy, and investment in disease prevention and healthcare

infrastructure. global programmes are long-term commitments, designed to be

scaleable, replicable and sustainable.

By working in partnership with NGOs and leading health organisations, Gsk believe it is

possible to achieve significant and long-lasting improvements in healthcare. This section

profiles one of the most ambitious programmes we are involved in the Global Allianceto Eliminate Lymphatic Filariasis, a partnership to eliminate a disfiguring and debilitating

tropical disease by contributing towards the worlds largest-ever drug donation.


11/22

Environmental sustainability.

GlaxoSmithKline has strengthened its commitment to the environmenttoo, setting new ambitious targets. Its goal is to reduce the environmental impact of ourvalue chain, from raw materials to product disposal, becoming carbon neutral by 2050.

They have already achieved a reduction of nearly 11% in greenhouse gas emissionssince 2006 which, although less than they had hoped, gives them a good foundation tobuild on in the coming years. have also reduced the amount of water we use by 16%since 2006, exceeding our 2% annual reduction target.

In focus: the global alliance toeliminate lymphatic filariasis anambitious partnership.

Hija from the village of Uyombo Vituka in Morogoro

region of Tanzania completed his primary

education in 1983. He couldnt afford to attendsecondary school but was able to find work to help

support himself and his family. All that changed in

1988 when he contracted lymphatic filariasis (LF).

LF is a debilitating disease which leads to severe

swelling of the limbs, breasts and genitals and

regular attacks of fever. It made walking very

difficult for Hija and left him too ill to work. And


12/22

then in 2008 a new programme was launched in Morogoro. Hija received two drugs

albendazole made by GSK and Mectizan made by Merck which were being

administered as part of a drug donation programme to eliminate LF in Tanzania. After

taking the drugs, Hijas symptoms improved: the swelling reduced and he suffered less

fever. He was soon able to walk again and help cultivate the familys land, and earn

money to support his family.

LF is a disease that many in the developed world have never heard about. It is a parasitic

disease transmitted by mosquitoes, which affects 120 million people in 83 countries. For

communities living in tropical countries its effects can be devastating, making it hard to

attend school or hold down a job and resulting in stigma and discrimination for many

sufferers. Since 2000 the prospects for these communities have improved significantly,

thanks to a unique collaboration the Global Alliance to Eliminate Lymphatic Filariasis.

Through the Alliance, GSK and its partners hope to completely rid the world of LF so that

millions of people never have to experience the disabling effects of this disease.

Ten years on from the launch of the Alliance, we have donated almost two billion tablets

of albendazole and hundreds of millions of people have been treated through mass drug

administrations in 54 countries.

The GSK factory manager in Cape Town says: We may be giving away this drug as part

of our community programmes, but we treat every batch we manufacture, every box we

ship as professionally and to the same high standards as though it was going to a paying

customer anywhere in the world.

Performance..Highlights from some of our key global programmes during 2010 are outlined below.

Investing in developing worldhealthcare infrastructure.The issue

Millions of people in the worlds Least Developed Countries (LDCs) lack access to basic

healthcare services.

What GSK is doing

In 2009 the chairman announced GSKs commitment

to becoming a partner in finding solutions to

healthcare delivery by reinvesting 20% of profits

(from our medicines and Consumer Healthcare

products) in Least Developed Countries (LDCs) into

local healthcare infrastructure. This amounts to

5m based on profits made in 2009 and 2010.


13/22

Results in 2010

To date gsk have committed 1.8m to a number of projects including: support for

maternal and child health in Sudan, Ethiopia and the Democratic Republic of

Congo, expanding a network of nurse-run clinics to improve access to essential

medicines in Rwanda; and improving access to water and sanitation in Cambodia

and Burma (Myanmar). In January 2011 gsk announced a global partnership with AMREF, Save the

Children and CARE International to build on these initial projects. Our aim is to

establish regional Healthcare Infrastructure Partnerships (HIPs) through which the

20% profits will be invested. The goal of the HIP is to strengthen the health

workforce in LDCs, with a focus on frontline health workers in the most rural and

marginalised communities. Through this structure, new initiatives in Yemen, Niger,

Sierra Leone, Angola, Zambia, Mozambique, Bangladesh, Nepal and Cambodia

have been prioritised for implementation in 2011.

Personal Hygiene and sanitation

education programme (Phase).The issueEvery year more than two million people die of diarrhoea-related disease, mostly

children in developing countries.

What GSK is doing

Gsk established PHASE in 1998 to reduce diarrhoea-related disease by encouraging

school children to wash their hands.

Results in 2010

PHASE reached 1.4 million children in 16 countries, meeting our goal to reach over one

million children. Highlights included: Fit for School, launched in the Philippines combining PHASE with a campaign to

promote regular tooth brushing

Our PHASE partners in India participated in Global Handwashing Day. Over 3,000

families in the Mumbai slums received a visit from school children conveying the

importance of hand washing
http://www.gsk.com/community/phase.htmhttp://www.gsk.com/community/phase.htm


14/22

PHASE in Uganda was extended to five new districts. So far, it has helped reduce

school absence from 24 % to 14 % participating districts.

African Malariapartnership

The issue

Every year up to 500 million people are affected by malaria and 800,000 die from

it, mostly in sub-Saharan Africa.

What GSK is doing

Our African Malaria Partnership aims to improve access to treatment and

prevention of malaria in sub-Saharan Africa through education of communities

and training to help community health volunteers diagnose cases of severe

malaria.

Results in 2010

Highlights from our partnership with Save the Children to reduce the risk of

malaria outbreaks in communities affected by flooding in north-east Kenya

included:

Training to help 32 health professionals improve malarial case

management
http://www.gsk.com/community/malaria/programmes.htmhttp://www.gsk.com/community/malaria/programmes.htm


15/22

Indoor residual spraying to control malarial outbreaks in 336 households,

14 schools and one prison

Distribution of 5,120 long-lasting insecticide-treated nets

Recruiting and training new community health volunteers.

Disaster response.The issue

Natural disasters such as earthquakes, hurricanes and floods have a devastating

effect on many communities each year.

What GSK is doing

Gsk provide humanitarian assistance to those affected by emergencies and

natural disasters. We donate cash and supplies of our products via humanitarian

aid organisations experienced at responding quickly to such events.

Results in 2010

Gave 250,000 to help the British Red Cross provide emergency safe

water and sanitation facilities for thousands of people affected by the

earthquake in Haiti
http://www.gsk.com/community/humanitarian_relief.htmhttp://www.gsk.com/community/humanitarian_relief.htm


16/22

Gave 170,000 in cash contributions to support communities affected by

the earthquake in Pakistan

Donated medicines, including 95,000 doses of hepatitis A vaccines,

antibiotics, analgesics and more than 6,000 dental hygiene kits to support

communities affected by the earthquake in Chile.

Community investment.

GlaxoSmithKline global community investment was 222 million ($345million) in2010 compared with 163 million ($254 million) in 2009. they value donations atcost (average cost of goods)


17/22


18/22

Breakdown of cash giving (%).


19/22

Plans and targets.

During 2011 Gsk will continue to focus on programmes that help to increase access tohealthcare and education.

Their plans include:

Expanding donation of albendazole to treat school-aged children in Africa for soil-transmitted helminths (intestinalworms), in addition to their annual commitmentto supply 600 million tablets for use in the Global Programme toEliminateLymphatic Filariasis.

Launching a global partnership with AMREF, Save the Children and CareInternational to improve healthcare infrastructure in the Least DevelopedCountries (LDC), as part of commitment to reinvest 20% of profits made in LDCsfrom medicines and Consumer Healthcare products. This will train communityhealthcare workers and help build the capacity of local healthcare systems.

Expanding Personal Hygiene and Sanitation Education programme to include oralhealthcare as well as handwashing.

Rolling out new programmes as part of GSKs partnership of the 2012 Olympic andParalympic Games. This will include 'Scientists in Sport', an education outreachprogramme to inspire young people into science, working in partnership with five

leading UK universities.

Continuing investment in science, technology, engineering and mathematics(STEM) education programs in the US to help ensure the future workforce hasnecessary qualifications and skills.


20/22

Acknowledgement.

I would like to thank Prof. Archana, thefaculty for Business

Ethics for assigning such an enlightening topicfor project work

and giving the choice of selecting the companyfor the same.

This has really helped in understanding themeticulous efforts &

Innovations the companies take to carry outtheir corporate social

Responsibility, and what impact it has on thesociety as a whole.


21/22

Bibliography.. http://www.gsk-india.com/

http://www.gsk.com/responsibility/index.htm

http://www.gsk.com/responsibility/cr-report-

2010/ethical-conduct/

http://www.gsk.com/responsibility/cr-report-2010/our-

work-with-communities/
http://www.gsk-india.com/http://www.gsk.com/responsibility/index.htmhttp://www.gsk.com/responsibility/cr-report-2010/ethical-conduct/http://www.gsk.com/responsibility/cr-report-2010/ethical-conduct/http://www.gsk.com/responsibility/cr-report-2010/our-work-with-communities/http://www.gsk.com/responsibility/cr-report-2010/our-work-with-communities/http://www.gsk-india.com/http://www.gsk.com/responsibility/index.htmhttp://www.gsk.com/responsibility/cr-report-2010/ethical-conduct/http://www.gsk.com/responsibility/cr-report-2010/ethical-conduct/http://www.gsk.com/responsibility/cr-report-2010/our-work-with-communities/http://www.gsk.com/responsibility/cr-report-2010/our-work-with-communities/


22/22

Corporate Social Responsibility Orgninal

Documents

Transcript of Corporate Social Responsibility Orgninal